Obicetrapib, alone or with ezetimibe, reduces atherogenic lipoprotein particles
ATLANTA — Obicetrapib, a novel cholesteryl ester transfer protein inhibitor, reduced atherogenic lipoprotein particles alone or in combination with ezetimibe, according to new data from the ROSE2 trial. As Healio previously reported, in the main results of ROSE2, the combination of obicetrapib (NewAmsterdam Pharma) and ezetimibe further reduced LDL in statin-treated patients with